U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB


(MARK ONE)

[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2000

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF 1934 FOR THE TRANSITION PERIOD FROM ________ TO __________


COMMISSION FILE NUMBER:


                       L.O.M. MEDICAL INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

<TABLE>

<S>                                         <C>                                      <C>
DELAWARE                                                                                                       98-0178784
 (State or other jurisdiction of            (Primary Standard Industrial             (I.R.S. Employer Identification No.)
incorporation or organization)               Classification Code Number)

<CAPTION>

<S>                                                                                                              <C>
 #3-1482 Springfield Road , Kelowna, British Columbia, Canada                                                    V1Y  5V3
(Address of principal executive offices)                                                                        (Zip Code)
                                    (250) 762-7552(Issuer's Telephone Number, including Area Code)
</TABLE>



                              Thomas E. Stepp, Jr.
                              Stepp & Beauchamp LLP
                           1301 Dove Street, Suite 460
                         Newport Beach, California 92660
                             Telephone: 949.660.9700
                             Facsimile: 949.660.9010
            (Name, Address and Telephone Number of Agent for Service)


                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check  whether  the issuer  (1) has filed all  reports  required  to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing requirements for the past 90 days.
[x] Yes [ ] No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity,  as of the latest  practical  date. As of November 30, 2000,  there were
6,072,810  shares of the  issuer's  $.001  par value  common  stock  issued  and
outstanding.


<PAGE>




L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Interim Consolidated Balance Sheet
($ United States)

November 30, 2000 and May 31, 2000

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------
                                                                             November 30,              May 31,
                                                                                     2000                 2000
                                                                              (Unaudited)
-------------------------------------------------------------------------------------------------------------------
<S>                                                                         <C>                  <C>
Assets

Current assets
     Cash and cash equivalents                                              $   1,121,519        $     959,318
     Accounts receivable                                                           24,945               21,070
     Prepaid expenses                                                              11,993                6,820
-------------------------------------------------------------------------------------------------------------------
                                                                                1,158,457              987,208

Advances and deposits                                                             117,395               42,000

Patent costs                                                                       10,420               12,504

Fixed assets (note 2)                                                              44,942               47,124

-------------------------------------------------------------------------------------------------------------------
                                                                            $   1,331,214        $   1,088,836
-------------------------------------------------------------------------------------------------------------------

Liabilities and Stockholders' Equity

Current liabilities
     Accounts payable and accrued liabilities                               $      24,112        $      27,791

Redeemable preferred shares (note 3)                                              301,727              301,727

Share subscriptions (note 4(b))                                                   133,711              185,513

Stockholders' equity
     Capital stock (note 4)                                                         6,072                5,846
     Additional paid in capital                                                 2,853,244            2,201,056
     Deficit accumulated during the development stage                          (2,020,956)          (1,666,401)
     Accumulated other comprehensive income                                        33,304               33,304
-------------------------------------------------------------------------------------------------------------------
                                                                                  871,664              573,805

-------------------------------------------------------------------------------------------------------------------
                                                                            $   1,331,214        $   1,088,836
-------------------------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to interim consolidated financial statements


                                       2

<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Interim Consolidated Statement of Loss
($ United States)

For the six  months  ended  November  30,  2000  and  1999  and  cumulative from
   inception (March 17, 1997) to November 30, 2000
(Unaudited - Prepared by Management)

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------
                                                        From Inception
                                                      (March 17, 1997)               2000                 1999
                                                    to November 30, 2000
-------------------------------------------------------------------------------------------------------------------
<S>                                                    <C>                  <C>                  <C>

Expenses
     Advertising                                           $    14,135         $      --            $         5
     Amortization                                               56,070               9,510                8,247
     Automotive                                                 53,217               8,710                8,187
     Consulting fees                                           190,685              66,458               20,981
     Conventions and seminars                                    2,300               2,300                 --
     Design plans                                               10,911                --                   --
     Director's fees                                            24,528               3,000                1,717
     Foreign exchange loss (gain)                               14,344                (932)              (1,721)
     Freight                                                     1,747               1,747                 --
     Insurance                                                  23,225              10,670                 --
     Interest and bank charges                                  12,513               3,622                2,289
     Legal and accounting                                      251,698              77,615               28,331
     Licences, fees and dues                                     4,500                 159                  185
     Management fees and wages                                 469,874             103,610               76,838
     Office and administration                                 215,292              39,549               20,568
     Product development                                        30,848               4,264                 --
     Promotion and entertainment                                16,666                 861                1,482
     Prospectus and share issuance                              10,271              10,271                 --
     Rent                                                      141,952              26,910               17,717
     Repairs and maintenance                                     2,445                 129                 --
     Storage                                                       853                 853                 --
     Telephone and utilities                                    44,318               4,331                6,312
     Travel                                                     61,692               8,988               10,250
     Video production                                           26,783                 511                2,929
     Write down of inventory                                    55,734                --                   --
     Write down of product rights and patent costs             374,128                --                   --
-------------------------------------------------------------------------------------------------------------------
                                                             2,110,729             383,136              204,317

-------------------------------------------------------------------------------------------------------------------
Loss from operations                                        (2,110,729)           (383,136)            (204,317)

Other income
     Interest income                                            89,773              28,581                6,488
-------------------------------------------------------------------------------------------------------------------
                                                            (2,020,956)           (354,555)            (197,829)


-------------------------------------------------------------------------------------------------------------------
Net loss                                                   $(2,020,956)        $  (354,555)         $  (197,829)
-------------------------------------------------------------------------------------------------------------------


Loss per common share, basic and diluted                   $     (0.44)        $     (0.06)         $     (0.03)
-------------------------------------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------------------------------------
Weighted average common shares, basic diluted                4,543,686           5,971,538            5,668,414
-------------------------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to interim consolidated financial statements

                                       3

<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Interim Consolidated Statement of Loss
($ United States)

For the three months ended  November 30, 2000 and 1999  (Unaudited - Prepared by
Management)

<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------
                                                                         2000                 1999
---------------------------------------------------------------------------------------------------------

<S>                                                              <C>                  <C>
Expenses
     Advertising                                                 $      --                  $         5
     Amortization                                                      4,755                      4,205
     Automotive                                                        4,078                      5,401
     Consulting fees                                                  39,136                     12,903
     Conventions and seminars                                           --                         --
     Design plans                                                       --                         --
     Director's fees                                                   3,000                      1,717
     Foreign exchange loss (gain)                                       (907)                    (2,550)
     Freight                                                             665                       --
     Insurance                                                         5,113                       --
     Interest and bank charges                                         1,789                      1,494
     Legal and accounting                                             51,751                     11,592
     Licences, fees and dues                                             159                        185
     Management fees and wages                                        43,176                     42,434
     Office and administration                                         9,529                      5,122
     Product development                                               1,729                       --
     Promotion and entertainment                                         334                      1,029
     Prospectus and share issuance                                     6,921                       --
     Rent                                                              8,734                      7,452
     Repairs and maintenance                                              64                       --
     Storage                                                             386                       --
     Telephone and utilities                                           1,922                      3,679
     Travel                                                            7,268                      9,603
     Video production                                                   --                        2,929
     Write down of inventory                                            --                         --
     Write down of product rights and patent costs                      --                         --
---------------------------------------------------------------------------------------------------------
                                                                     189,602                    107,200

---------------------------------------------------------------------------------------------------------
Loss from operations                                                (189,602)                  (107,200)

Other income
     Interest income                                                  14,922                      3,604
---------------------------------------------------------------------------------------------------------
                                                                    (174,680)                  (103,596)


---------------------------------------------------------------------------------------------------------
Net loss                                                         $  (174,680)               $  (103,596)
---------------------------------------------------------------------------------------------------------


Loss per common share, basic and diluted                         $     (0.03)               $     (0.02)

Weighted average common shares, basic diluted                      6,034,358                  5,557,782
---------------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to interim consolidated financial statements

                                       4

<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Interim Consolidated Statement of Cash Flows
($ United States)

For the six  months  ended  November  30,  2000  and  1999  and  cumulative from
   inception (March 17, 1997) to November 30, 2000
(Unaudited - Prepared by Management)

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------
                                                            From inception
                                                          (March 17, 1997)               2000                 1999
                                                        to November 30, 2000
-----------------------------------------------------------------------------------------------------------------------

<S>                                                          <C>                  <C>                  <C>
Operating activities
   Net loss for the period                                   $(2,020,956)             (354,555)        $  (197,829)

   Items not involving cash
     Amortization                                                 56,070                 9,510               8,247
     Gain on sale of capital asset                                (2,659)                 --                  --
     Write down of inventory                                      55,734                  --                  --
     Write down of product rights                                374,128                  --                  --

   Changes in non-cash working capital
     Accounts receivable                                         (24,945)               (3,875)              2,474
     Prepaid expenses                                            (11,993)               (5,173)                  1
     Accounts payable and accrued liabilities                     24,112                (3,679)            (16,388)
     Inventory purchases                                         (55,734)                 --                  --
-----------------------------------------------------------------------------------------------------------------------
                                                              (1,606,243)             (357,772)           (203,495)
Financing
     Issuance of capital stock                                 2,006,072               466,901             166,171
     Proceeds from subscriptions for shares                      986,955               133,711              20,150
----------------------------------------------------------------------------------------------------------------------
                                                               2,993,027               600,612             186,321
Investing
     Acquisition of fixed assets                                 (96,963)               (5,244)               --
     Acquisition of product rights                               (90,577)                 --                  --
     Proceeds on disposition of capital asset                      6,189                  --                    44
     Advances and deposits                                      (117,395)              (75,395)               --
-----------------------------------------------------------------------------------------------------------------------
                                                                (298,746)              (80,639)                 44

Foreign currency translation adjustment                              177                  --                  --
Other comprehensive income                                        33,304                  --                  --
-----------------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash                                    1,121,519               162,201             (17,130)

Cash and cash equivalents, beginning of period                      --                 959,318             346,646

-----------------------------------------------------------------------------------------------------------------------
Cash and cash equivalents, end of period                     $ 1,121,519           $ 1,121,519         $   329,516
-----------------------------------------------------------------------------------------------------------------------

Supplementary information:
   Interest paid                                             $      --             $      --           $      --
   Income taxes paid                                                --                    --                  --
Non-cash financing and investing activities:
   Issuance of redeemable preferred shares
     for product rights                                          309,677                  --                  --
-----------------------------------------------------------------------------------------------------------------------
   Common shares issued for conversion of
     share subscriptions                                     $   248,244           $   185,513         $    62,731
-----------------------------------------------------------------------------------------------------------------------
</TABLE>

See accompanying notes to interim consolidated financial statements

                                       5

<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Stockholders' Equity and Comprehensive Income
$ United States

For the period from inception on March 17, 1997 to November 30, 2000  (Unaudited
- Prepared by Management)

<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------------------
                                                                             Deficit
                                    Capital Stock                           Accumulated    Accumulated
                               ----------------------         Additional     During the       Other          Total
                                  Number                       Paid in      Development   Comprehensive  Stockholders'
                                of Shares      Amount          Capital         Stage          Income        Equity
---------------------------------------------------------------------------------------------------------------------
<S>                                <C>         <C>           <C>           <C>            <C>            <C>
Common shares issued                       3   $         1   $      --     $      --      $      --      $      --

Comprehensive income:
  Loss                                  --            --            --        (138,272)          --         (138,272)
  Foreign currency translation          --            --            --            --           13,582         13,582
---------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)             --            --            --        (138,272)        13,582       (124,690)

---------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1997                      3             1          --        (138,272)        13,582       (124,689)

Common shares issued
  net of share issue costs         2,410,944         2,410       472,355          --             --          474,765

Common shares issued
  net of shares issue costs        3,072,300         3,072       601,928          --             --          605,000

Comprehensive income:
  Loss                                  --            --            --        (293,239)          --         (293,239)
  Foreign currency translation          --            --            --            --           (7,294)        (7,294)
---------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)             --            --            --        (293,239)        (7,294)      (300,533)

---------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1998              5,483,247         5,483     1,074,283      (431,511)         6,288        654,543

Common shares issued
  net of share issue costs            36,300            36        96,726          --             --           96,762

Comprehensive income:
  Loss                                  --            --            --        (726,055)          --         (726,055)
  Foreign currency translation          --            --            --            --           17,038         17,038
---------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)             --            --            --        (726,055)        17,038       (709,017)

---------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1999              5,519,547         5,519     1,171,009    (1,157,566)        23,326         42,288

Common shares issued
  net of share issue costs           307,610           308       967,335          --             --          967,643

Common shares issued for
  conversion of share
  subscriptions                       19,302            19        62,712          --             --           62,731

Comprehensive income:
  Loss                                  --            --            --        (508,835)          --         (508,835)
  Foreign currency translation          --            --            --            --            9,978          9,978
---------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)             --            --            --        (508,835)         9,978       (498,857)

---------------------------------------------------------------------------------------------------------------------
Balance, May 31, 2000              5,846,459   $     5,846   $ 2,201,056   $(1,666,401)   $    33,304    $   573,805
---------------------------------------------------------------------------------------------------------------------
</TABLE>

                                        6


<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated   Statements  of  Stockholders'  Equity  and  Comprehensive  Income
(continued)
$ United States

For the period from inception on March 17, 1997 to November 30, 2000  (Unaudited
- Prepared by Management)

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------
                                                                             Deficit
                                       Capital Stock                       Accumulated     Accumulated
                                  -------------------------  Additional     During the        Other          Total
                                    Number                   Paid in       Development    Comprehensive   Stockholders'
                                  of Shares     Amount       Capital          Stage          Income         Equity
-----------------------------------------------------------------------------------------------------------------------------
<S>                               <C>          <C>           <C>           <C>            <C>           <C>
Balance, May 31, 2000,
  carried forward                  5,846,459   $     5,846   $ 2,201,056   $(1,666,401)   $    33,304   $   573,805

Common shares issued for
  cash net of share issue
  costs of $83,227                   169,270           169       466,732          --             --         466,901

Common shares issued on
  conversion of share
  subscriptions                       57,081            57       185,456          --             --         185,513

Comprehensive income:
  Loss                                  --            --            --        (354,555)          --        (354,555)
  Foreign currency translation          --            --            --            --             --            --
-----------------------------------------------------------------------------------------------------------------------------
Comprehensive income (loss)             --            --            --        (354,555)          --        (354,555)

-----------------------------------------------------------------------------------------------------------------------------
Balance, Nov 30, 2000              6,072,810   $     6,072   $ 2,853,244   $(2,020,956)   $    33,304   $   871,664
-----------------------------------------------------------------------------------------------------------------------------
</TABLE>


                                       7

<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
($ United States)

(Unaudited - Prepared by Management)

--------------------------------------------------------------------------------

L.O.M.  Medical  International Inc. was incorporated on March 17, 1997 under the
General  Corporation Laws of Delaware.  It conducts  research and development on
new  products  in the  medical  field  and has filed a patent  application  on a
retractable  syringe.  Operations  effectively  commenced on June 1, 1997. These
interim consolidated financial statements should be read in conjunction with the
annual financial statements for the year ended May 31, 2000 filed under cover of
Form 10-KSB.

1. Significant accounting policies:

     a)   Going concern

          These  financial  statements  have been  prepared by management on the
          going concern basis in accordance with generally  accepted  accounting
          principles  in the United  States,  which assumes the  realization  of
          assets and  liquidation of liabilities  and  commitments in the normal
          course of business. As shown in the consolidated financial statements,
          to date,  the Company has generated no revenues and has  accumulated a
          deficit  since  inception of  $2,020,956.  This  factor,  among others
          raises  substantial doubt about the Company's ability to continue as a
          going concern. The Company's ability to continue as a going concern is
          dependent on its ability to generate future profitable  operations and
          receive  continued  financial  support from its stockholders and other
          investors.

          Management's  plans  with  respect  to  generating  future  profitable
          operations include future sales of the retractable  syringe as well as
          additional  funding from  stockholders in the form of additional share
          subscriptions. There can be no assurance that any such financings will
          be  available.  Failure to obtain  adequate  financing  will cause the
          Company to curtail operations.

     b)   Basis of presentation and consolidation

          The  consolidated  financial  statements  include the  accounts of the
          Company and its 96% owned  subsidiary,  L.O.M.  Laboratories  Inc. All
          significant   inter-company   transactions   and  balances  have  been
          eliminated.

     c)   Translation of financial statements

          The Company's functional currency is the United States dollar.
          The Company's  subsidiary,  L.O.M.  Laboratories  Inc., has a Canadian
          dollar functional currency.

     d)   Patent costs

          Patent  costs  relate to amounts paid to acquire the rights to produce
          and distribute  products as well as the costs  associated  with patent
          applications.




                                       8

<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 2
($ United States)

(Unaudited - Prepared by Management)

--------------------------------------------------------------------------------

1.   Significant accounting policies (continued):

     d)   Patent costs (continued)

          These costs are being  amortized  on a  straight-line  basis over five
          years.

     e)   Fixed assets

          Fixed assets are recorded at cost.  Amortization is provided using the
          following  methods and annual rates which are intended to amortize the
          cost of the assets over their estimated useful life:

--------------------------------------------------------------------------------
         Asset                                      Method             Rate
--------------------------------------------------------------------------------

         Leasehold improvements              Straight-line              20%
         Computer software                   Straight-line             100%
         Equipment                       Declining balance              30%
         Furniture and fixtures          Declining balance              20%
--------------------------------------------------------------------------------


     f)   Income taxes

          The  Company  accounts  for  income  taxes by the asset and  liability
          method. Under the asset and liability method,  deferred tax assets and
          liabilities   are   recognized   for  the  future   tax   consequences
          attributable to differences  between the financial  statement carrying
          amounts of existing assets and  liabilities  and their  respective tax
          bases and operating  loss and tax credit  carryforwards.  Deferred tax
          assets and  liabilities  are measured using enacted tax rates expected
          to apply to  taxable  income  in the  years in which  those  temporary
          differences  are expected to be  recovered  or settled.  The effect on
          deferred  tax  assets  and  liabilities  of a change  in tax  rates is
          recognized in income in the period that includes the enactment date.

     g)   Management estimates

          The  preparation of financial  statements in conformity with generally
          accepted  accounting  principles  in  the  United  States  of  America
          requires  management to make estimates and assumptions that affect the
          reported   amounts  of  assets  and  liabilities  and  disclosures  of
          contingent  assets  and  liabilities  at the  date  of  the  financial
          statements  and the reported  amounts of revenues and expenses  during
          the  reporting   period.   Actual  results  could  differ  from  those
          estimates.

     h)   Financial instruments

          The  fair  values  of the  Company's  cash,  accounts  receivable  and
          accounts payable and accrued  liabilities  approximate  their carrying
          values  due  to  the  relatively  short  periods  to  maturity  of the
          instruments.  It is  not  possible  to  arrive  at a  fair  value  for
          redeemable preferred shares as a public market for this stock does not
          exist.  The maximum  credit risk exposure for all financial  assets is
          the carrying amount of those assets.


                                       9

<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 3
($ United States)

(Unaudited - Prepared by Management)

--------------------------------------------------------------------------------

1.   Significant accounting policies (continued):

     i)   Loss per share

          Loss per share has been calculated  using the weighted  average number
          of common shares outstanding during the period.

     j)   Quarterly financial reporting

          In the opinion of management,  all  adjustments  (consisting of normal
          recurring  items)  necessary  for  the  fair   presentation  of  these
          unaudited  financial  statements in conformity with generally accepted
          accounting principles have been made.

2.   Fixed assets:

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------
                                                                             November 30,              May 31,
                                                                                     2000                 2000
-------------------------------------------------------------------------------------------------------------------
                                                            Accumulated          Net book             Net book
                                               Cost        amortization             value                value
-------------------------------------------------------------------------------------------------------------------
<S>                                     <C>                <C>               <C>                 <C>
     Leasehold improvements             $    27,919        $     13,959      $     13,960        $      16,752
     Computer software                        5,446               2,302             3,144                4,192
     Equipment                               29,844              16,368            13,476               12,588
     Furniture and fixtures                  23,354               8,992            14,362               13,592

-------------------------------------------------------------------------------------------------------------------
                                        $   86,563         $     41,621      $     44,942        $      47,124
-------------------------------------------------------------------------------------------------------------------
</TABLE>

3.   Redeemable preferred shares:

     The Company's  subsidiary has redeemable  preferred  shares  outstanding as
follows:

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------
                                                                             November 30,              May 31,
                                                                                     2000                 2000
-------------------------------------------------------------------------------------------------------------------
<S>                                                                               <C>                  <C>
     Issued:
         4,000 Class C preferred shares with a par
           value of $100 Cdn redeemable at $110.16 Cdn per share
           at the option of the holder. Each share is entitled
           to a fixed non-cumulative dividend at the rate of 9% per annum
           payable at such times as determined by the Directors.                  301,727              301,727
-------------------------------------------------------------------------------------------------------------------
</TABLE>

4.   Capital stock:

     a)   Authorized:

          50,000,000  Common  shares  with a par value of $.001  each
          5,000,000 Preferred shares with a par value of $.001 each

                                       10

<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements, page 4
($ United States)

(Unaudited - Prepared by Management)

--------------------------------------------------------------------------------

4.   Capital stock (continued):

     b)   Share subscriptions:

          Subsequent  to November 30, 2000,  the Company  issued  41,142  common
          shares at $3.25 per share for net  proceeds  of  $133,711  which  were
          received prior to November 30, 2000.

     c)   Stock option plan:

          3,000,000  common shares of the Company are reserved for issuance upon
          exercise of stock  options.  As at November 30, 2000, no stock options
          have been granted.

5.   Related party transactions:

     During the period the Company entered into the following  transactions with
related parties:

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------
                                                                                     2000                 1999
-------------------------------------------------------------------------------------------------------------------

<S>                                                                        <C>                   <C>
     Accounting fees paid to a director                                    $       24,120        $       6,718
     Management fees paid to president                                             60,918               60,000
     Office and administration fees paid to president's spouse                     18,275               18,000
     Office and administration fees paid to an individual
       related to the president                                                    10,008                8,040
     Management fees to a company controlled by the president                      20,000                  --
     Rent paid to a company controlled by the president                            18,885               17,717

-------------------------------------------------------------------------------------------------------------------
</TABLE>

     These  transactions are in the normal course of operations and are measured
     at the exchange  amount of  consideration  established and agreed to by the
     related parties.

6.   Commitments:
     The Company is obligated to make future lease payments for it's offices as
follows:

         2001                                           $  10,536

         2002                                           $  21,072

         2003                                           $  21,072

         2004                                           $  21,072

         2005                                           $  21,072



                                       11

<PAGE>



Item 2. Management's Discussion and Analysis or Plan of Operation

Development of the Company

L.O.M.  Medical  International  Inc., a Delaware  corporation  ("Company"),  was
incorporated  in the State of Delaware on March 17, 1997. Our executive  offices
are located at #3-1482  Springfield  Road,  Kelowna,  B. C., Canada V1Y 5V3. The
Company's telephone number is 250.762.7552.

For  purposes  of  clarification,  anytime  the symbol  "US" is used within this
Annual  Report of Form 10-KSB,  it refers to the currency of the United  States.
Anytime the symbol "CDN" is used, it refers to the currency of Canada.

Business of the Company

The  Company was  incorporated  for the purpose of  researching  and  developing
health  care  products.  Our goal is to become an  innovator  and  provider of a
retractable  syringe  ("Syringe") and related  products and  technologies to the
health care market. We also hope to successfully market and distribute a line of
eye care  products.  We have  successfully  patented  and  licensed  products in
seventy countries including the United States and Canada. We plan to develop new
and improved  products and provide the health care industry  with better,  safer
products throughout the world.

The Retractable Syringe

We believe the Syringe will change standard  disposal methods for used syringes.
We have  developed  a product  designed  to  function  as a standard  hypodermic
syringe  that we believe is safer to the  caregiver  or health care  worker.  We
believe that the  Syringe's  unique  design will allow health care  providers to
avoid direct contact with used needles.  The Syringe is covered by United States
Patent No. 5,868,713 dated February 9, 1999, and international patents have been
filed in 24 different countries.

Once the needle is injected, the user simply has to press the plunger top gently
with his or her thumb to  automatically  retract  the needle into its own sealed
chamber. The needle is now hidden where it remains locked in place and cannot be
used again.  The Syringe does not require a health care worker to use both hands
to retract the needle after it has been used and withdrawn from the patient. The
Syringe  will  be  produced  in  standard  industry  sizes  from  1CC  to 20 CC,
inclusive.

We intend to promote  the Syringe as a safer and less  risk-oriented  instrument
for hospital  staff and health care  workers.  We are  optimistic  that doctors,
nurses,  and health care workers alike will  recognize and appreciate the safety
features of the Syringe because of its ease of "use-and-disposal" and its unique
"contaminate-prevention" characteristics.

It is  anticipated  that the products and  technologies  developed by us will be
offered to distributors on a worldwide basis, with an initial emphasis in Canada
and the United States. It is hoped that new product and technology ideas will be
generated  through  active  dialogues  among our  potential  customers,  and our
network  of  scientific  advisors.  We will also  participate  in  national  and
international conferences, and reviews of selected scientific literature.

Our  management  interacts  with a network  of  scientific  advisors  within the
industry,  including  members of  academic  institutions,  as well as  potential
customers.  We anticipate that these interactions will enable us to identify the
specialized  needs of those  potential  customers and to provide  innovative and
commercially   acceptable   products  and   technologies.   At  this  time,  our
relationship with scientific advisors and academic institutions is limited to an
advisory  relationship.  We  currently  perform  all of  our  own  research  and
development.  We have  currently  entered  into  agreements  with B.C.  Tech And
Phillips  Corporation for production of produce the prototype Syringe as well as
100,000 test units. The contract price is in the range of  US$400,000.00.  These
funds will be paid out over the next five months.

During the next five  months  there may be  significant  increases  to  staffing
levels. Dr. Simon Wood will run the research and development department.  We are
currently  interviewing  mid level  engineers  to assist with  computer  product
design requirements.

We anticipate  testing the Syringe in conjunction with teaching  universities in
Canada, Britain, and other constituents of the United Kingdom.


                                       12

<PAGE>




We are not currently  producing  commercial  quantities of products or currently
supplying any services to any third  parties.  No assurance can be given that we
will,  on a timely  basis,  be able to make the  transition  from  manufacturing
testing   quantities  of  the  Syringe  to  commercial   production   quantities
successfully or be able to arrange for contract manufacturing.

We anticipate  contracting out the first two years of production of the Syringe.
At the  end of  the  second  year  of  production,  we  anticipate  engaging  in
significant  discussions regarding the potential for the construction of our own
production facility. We recognize that the construction of a production facility
will be contingent upon us having reached our sales and profit  projections.  We
anticipate  this issue will be presented  for vote by the Board of Directors and
shareholders.  We have begun  negotiations  to set up a  manufacturing  plant in
Ireland.  However,  such negotiations have not progressed beyond the preliminary
discussions discussed in our previous filings.

The Eye Care System

We have  invented  and  developed an  insertion  and storage  device for contact
lenses  (the "Eye Care  System"),  which is a method of handling  and  inserting
contact  lenses.  We have developed the following  components and solutions that
will be used together with the Eye Care System insertion and storage products:

     o    a  medical  inserter  that  will  remove  contact  lenses in a medical
          emergency situation for use by hospital medical staff and paramedics;

     o    disposable and replacement inserter ends;

     o    additional storage cups and caps; and

     o    all soaking and  disinfecting  solutions  that are to be used with the
          Eye Care System inserter.

The Eye Care  System is designed  so that the  practitioner  will no longer have
direct hand or finger contact with the contact lens when fitting the patient. We
believe that the design of the system will reduce the risk of contamination  and
infection to the patient.  We have  developed a liquid  cleaner for the Eye Care
System that  quickly  cleans  contact  lenses.  We have  obtained  Food and Drug
Administration Approval ("FDA") for the Eye Care System product.

We have  completed  market testing and believe that the Eye Care System was well
received at the  American  Optometrists  Association.  convention  in  Montreal,
Canada,   where  approximately  30,000  units  were  distributed  to  opticians,
optometrists  and pharmacies.  We have completed the formulation of contact lens
solutions and copyrights  covering these products have been registered.  We have
completed  the design and labeling of the Eye Care  System.  We believe that the
eye-care products are ready for marketing and distribution.

The target markets for the distribution for the Eye Care System product include,
but are not  necessarily  limited  to,  hospitals  and  clinics,  including  and
optometrists and opticians.

The eye care  products  are  currently  produced  in  Canada.  We own all of the
necessary injection molds. We will contract out for the production of components
needed for the  assembly  and  packaging  of the eye care  products.  The actual
assembly and packaging will be subcontracted out at this time.

We have produced 33,000 units of our eye care inserters,  which will be used for
demonstrations.  As such, we have not inventoried the units but expensed them in
the past financial statements and net realizable value is anticipated to be nil.
We  currently  have  the  ability  to  subcontract  out  for the  production  of
commercial  quantities of our eye care products.  We currently have dies with an
output  capacity of 150,000  units.  There is a second set of dies designed that
will have a 300,000 unit capacity which would allow the production of a total of
450,000 units of eye care products per month.

We have FDA  approval  to market  our line of eye care  products  in the  United
States and have the necessary  Canadian  approval to market eye-care products in
Canada.  We are reviewing various contracts with third parties to market the Eye
Care System in Canada as well as the United States.

We will focus our activities  over the next several months on the production and
launch of the syringe.  When that is finalized,  we will implement our marketing
plan for the Eye Care System products.

                                       13

<PAGE>

Skin Care Products

We are currently in the first phase of licensing  agreements  with Neuro-Skin in
Germany  the  owners  of the  rights to a line of skin  care  products.  We have
invested  approximately  $117,000 to date to pay for  licensing  agreements  and
patents in North  America.  We are sending Dr.  Simon Wood to Germany to perform
additional due diligence with regards to licensing rights.

Business of the Company's Subsidiary

There has been no activity in the subsidiary  this quarter.  For the foreseeable
future the subsidiary will be inactive.

Future Capital Requirements

We will require additional cash to implement our business strategies,  including
cash  for  (i)  payment  of  increased   operating  expenses  and  (ii)  further
implementation of our business strategies.  No assurance can be given,  however,
that we will have access to the capital markets in the future, or that financing
will be available on acceptable terms to satisfy our cash requirements necessary
to  implement  the  business  strategies.  The  inability  to access the capital
markets or obtain  acceptable  financing could have a material adverse effect on
our results of operations and financial condition.

Our forecast of the period of time through which the financial resources will be
adequate to support the operations is a forward-looking  statement that involves
risks and  uncertainties,  and actual results could vary as a result of a number
of factors.

We anticipate having to raise additional capital over the next several months in
order to develop,  promote,  produce and distribute our proposed products.  Such
additional   capital  may  be  raised  through   additional  public  or  private
financings,  as well as  borrowings  and other  resources.  To the  extent  that
additional  capital  is raised  through  the sale of  equity  or  equity-related
securities,  the  issuance of such  securities  could  result in dilution of the
stockholders.

There can be no assurance that additional funding will be available on favorable
terms, if at all. If adequate funds are not available within the next 12 months,
we may be  required  to  curtail  operations  significantly  or to obtain  funds
through entering into  arrangements with  collaborative  partners or others that
may require us to relinquish rights to certain of our products that we would not
otherwise  relinquish.  However,  we  believe  that we are  poised  to  maintain
long-term liquidity.

Business Risks

L.O.M.  Medical  International  Inc. is exposed to a variety of business  risks,
some of which are inherent to all competitive  commercial enterprises and others
that are  specific to the medical  products  industry.  Management  endeavors to
limit all specific risk factors through its disciplined  management of operation
and financial strategies.

Financial Risks

Our business plans are aggressive in nature.  Continued rapid business expansion
will consume valuable  working capital and result in significant  demand on cash
flow from operations over the next few quarters. We expect that existing capital
resources  and  contributions  from profits will not be  sufficient  to fund the
business plans as represented without assembling  additional funds from external
sources.

Business Cycles and Risks of Cost Overruns

The sale  and  implementation  of our  products  involves  a  reasonable  market
penetration.  Failure to secure reasonable market penetration could have adverse
effects on the general business of L.O.M. Medical International Inc., results of
operations and our financial condition.

                                       14

<PAGE>


Fluctuations in Financial Results

Our operating  results will  fluctuate,  depending on factors such as the demand
for products,  the size and timing of contracts,  new products and enhancements,
price  competition,  changes in  operating  expenses and  personnel  and general
economic factors.  Therefore,  actual financial  results may vary  significantly
from those projected by management.

Third-Party Claims for Infringement

We are not aware that any of our products infringe on the proprietary  rights of
third parties.  There can be no assurance,  however, that third parties will not
claim such  infringements by us with respect to current or future products.  Any
such claims,  with or without merit,  could be time consuming,  result in costly
litigation, or cause product or shipment delays. Any of the foregoing could have
adverse effects on our business, results of operations or financial condition.

Dependence of Single Product Line

Concentration  of sales in a single product line for the medical health industry
represents a substantial risk should market conditions deteriorate.

Foreign Currency

Our business plans of L.O.M. Medical International Inc. are primarily focused on
the  penetration  in the  United  States  and  subsequently  worldwide  markets,
therefore, we will be subject to the risk of foreign currency fluctuations.

Competition and Sales Channels

Several  companies  compete  with us. in the syringe  market and there are a few
competitors  in the safety syringe  market.  Most are  substantially  larger and
possess greater financial resources than us. Our future success, however, relies
on achieving superior product  development through greater focus on the needs of
the market and faster response to evolving customer  requirements.  There can be
no assurance,  however,  that competitors will not develop products  superior to
our  products or achieve  greater  market  acceptance  due to  marketing,  sales
channels or other factors.

Dependence on Large Distributors

We will rely in part on business  partners for the distribution of our products.
This includes a few large  distributors in the United States.  We ay be impacted
by negative business cycles or events  experienced by these  distributors.  This
may lead to a short or long term reduction in revenue.

Human Resource Risks and Growth

Our  success is  largely  dependent  on the  performance  of our key  employees.
Failure to attract and retain key employees with necessary  skills could have an
adverse  impact upon our growth and  profitability.  Our business is expected to
grow  rapidly  over  the  next  three  years.  This  expansion  will  result  in
substantial  growth in the number of  employees,  the scope of our operating and
financial systems and the geographic area of its operations.  This increases the
responsibilities for both existing and new management personnel.  Our ability to
support the  projected  growth of our  business  will be  dependent  upon having
highly  trained  personnel  in place to conduct  pre-sales  activities,  product
implementation  and other customer support  services.  Future operating  results
will  depend on the ability of our key  managers  and  employees  to continue to
implement and improve our operational,  customer support and financial  systems.
There can be no  assurance  that we will be able to manage any future  expansion
successfully, which could adversely affect the our results of operations and the
financial health.

Production and Quality Control

The manufacturing of products involves a number of steps and requires compliance
with  stringent  quality  control   specifications  imposed  on  us  by  various
regulators.  We may not be able to quickly replace manufacturing  capacity if we
were unable to use our manufacturing  facilities as a result of a fire,  natural
disaster (including  earthquake),  equipment failure or other difficulty,  or if
such  facilities  are  deemed not in  compliance  with the  various  regulators'
requirements  and

                                       15

<PAGE>

the  non-compliance  could not be rapidly  rectified.  The  inability or reduced
capacity to  manufacture or have  manufactured  any of our products would have a
material adverse effect on the business and results of operations.

Government Standards and Regulations

Our  products  will be subject to  numerous  foreign  government  standards  and
regulations  that are  continually  being amended.  Although we will endeavor to
satisfy foreign  technical and regulatory  standards,  there can be no assurance
that our products will comply with foreign government standards and regulations,
or changes  thereto,  or that it will be cost effective to redesign our products
to  comply  with such  standards  or  regulations.  The  inability  to design or
redesign products to comply with foreign standards could have a material adverse
effect on our business, financial condition and results of operations.

Product Liability Risk

Our  business  will  expose us to  potential  product  liability  risks that are
inherent in the testing,  manufacturing and marketing of medical products. We do
not currently have product  liability  insurance,  and there can be no assurance
that we will be able to obtain or maintain such  insurance on  acceptable  terms
or, if obtained,  that such insurance  will provide  adequate  coverage  against
potential liabilities.

We face an inherent  business  risk of exposure to product  liability  and other
claims in the event that the development or use of our technology or products is
alleged to have resulted in adverse effects.  Such risk exists even with respect
to those products that are manufactured in licensed and regulated  facilities or
that otherwise possess regulatory  approval for commercial sale. There can be no
assurance that we will avoid significant product liability  exposure.  There can
be no  assurance  that  insurance  coverage  will be  available in the future on
commercially  reasonable  terms,  or at all,  or  that  such  insurance  will be
adequate to cover potential product liability claims or that a loss of insurance
coverage  or the  assertion  of a product  liability  claim or claims  would not
materially  adversely  affect our business,  financial  condition and results of
operations.

While we have taken,  and will continue to take, what we believe are appropriate
precautions,  there can be no assurance that we will avoid significant liability
exposure.  An inability to obtain product liability insurance at acceptable cost
or to otherwise protect against potential product liability claims could prevent
or inhibit the  commercialization  of the products.  A product  liability  claim
could have a material  adverse effect on the business,  financial  condition and
results of operations.

Liquidity

We believe  that we are poised to maintain  our  liquidity  over the next twelve
months.  Our business plan indicates  significant  demand on cash flow.  This is
based  upon cash flow  projections  prepared  by us.  Additional  funds  will be
required to fulfill our projected business plans.  However,  we will curtail our
plans if  necessary  to maintain the  liquidity  of the  company.  However,  the
forecast for the period of time through  which the financial  resources  will be
adequate to support our operations is a forward-looking  statement that involves
risks and  uncertainties,  and actual results could fail as a result of a number
of factors.

We had cash  resources of $1,121,519 at November 30, 2000. At May 31, 2000,  and
had cash resources of $959,318.  At November 30, 2000, total current assets were
$1,158,457  and total current  liabilities  were $24,112.  At November 30, 2000,
total current assets  exceeded total current  liabilities by $1,134,345.  At May
31, 2000, total current assets were $987,208 and total current  liabilities were
$27,791.   At  May  31,  2000,  total  current  assets  exceeded  total  current
liabilities by $959,417. Because we are not generating any significant revenues,
our only external source of liquidity is the sale of our capital stock.

Results of Operations

We have not yet realized any significant  revenue from operations.  The net loss
from  operations  from March 17, 1997  (inception)  to November  30,  2000,  was
$2,020,956.  The net loss for the 6-month  period ended  November 30, 2000,  was
$354,555  compared to a loss of $197,829 for the 6-month  period ended  November
30,  1999.  The net loss for the  3-month  period  ended  November  30, 2000 was
$174,680 compared to a loss of $103,596 for the 3-month period ended

                                       16

<PAGE>


November 30, 1999. The net loss for the 12-month  period ended May 31, 2000, was
$508,835. Such losses were primarily the result of operational expenditures.

Item 2. Changes in Securities

We have offered to all shareholders of record,  one warrant for every two shares
held by each  shareholder.  Each warrant  entitles the holder of such warrant to
purchase one share of our common stock for $5.00 per share. Each warrant expires
by its own terms ninety days after the first transaction in the Company's shares
occurs on the  Over-the-Counter  Bulletin  Board. We have sold 107,111 of common
shares in the last quarter. Item 3. Defaults Upon Senior Securities

None

Item 4. Submission of Matters to Vote of Security Holders

None

Item 5. Other Information

None

Item 6. Exhibits and Reports on Form 8-K

On November 3, 2000, the Registrant accepted the resignation of Dr. John Gergely
as a director.  Dr.  Gergely  left to honor other  career  commitments,  and the
Registrant  is  not  aware  of  any  disagreements  on any  matter  relating  to
operation, policies or practice. The Form 8-K has been filed.

On December 1, 2000,  the  Registrant  accepted  the  resignation  of Mr.  Peter
McFadden as a director. Mr. McFadden left to honor other career commitments, and
the  Registrant  is not aware of any  disagreements  on any matter  relating  to
operation, policies or practice. The Form 8-K has been filed.









                                       17

<PAGE>




                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

Dated:   December 18, 2000                  L.O.M. Medical International, Inc.


                                            By:      /s/ John Klippenstein
                                                     --------------------------
                                                     John Klippenstein
                                            Its:     President




                                       18